Strategic report Governance & remuneration Financial statements Investor information Annual report on remuneration continued Non-Executive Directors fees Chairman and other Non-Executive Directors Letters of appointment The company aims to provide the Chairman and other NonThe terms of engagement of the Non-Executive Directors are Executive Directors with fees that are competitive with those paid set out in letters of appointment which are available for inspection by other companies of equivalent size and complexity, subject to at the companys registered ofce and at the AGM.
For each the limits contained in GSKs Articles of Association.
Non-Executive Director, his or her initial appointment and any subsequent re-appointment are subject to election and, thereafter, Chairmans fees periodic re-election by shareholders.
Chairman Sir Philip Hampton was appointed a Non-Executive Director on 1 January 2015, and received the standard annual The Non-Executive Directors letters of appointment do not fee for a Non-Executive Director of 85,000, until 1 April 2015, contain provision for notice periods or for compensation if their he then received fees of 350,000 per annum as Deputy appointments are terminated.
Since his appointment as Chairman at the conclusion The following table shows the date of the initial letter of of the AGM on 7 May 2015, his fees increased to 700,000 per appointment of each Non-Executive Director: annum.
He has elected to take 25% of his fees as GSK shares.
Non-Executive Director fees Date of letter of Non-Executive Director appointment Non-Executive Director fees were last increased in January 2013.
Sir Philip Hampton 25 September 2014 There were no increases to the supplemental fees.
A minimum of 25% of fees will continue to be delivered as shares deferred until Professor Sir Roy Anderson 28 September 2007 the Non-Executive Director steps down from the Board.
Vindi Banga 5 May 2015 The Non-Executive Directors fees applying since 1 January 2013 Dr Stephanie Burns 12 February 2007 are set out below: Stacey Cartwright 3 March 2011 Per annum Lynn Elsenhans 3 May 2012 Standard annual fee 85,000 Dr Jesse Goodman 23 December 2015 Supplemental fees Judy Lewent 3 March 2011 Chairman of the Audit & Risk Committee 80,000 Senior Independent Director and scientific Medical Experts 30,000 Sir Deryck Maughan 26 May 2004 Chairmen of the Remuneration and Corporate 20,000 Dr Daniel Podolsky 3 July 2006 Responsibility Committees Urs Rohner 3 October 2014 Non-Executive Director undertaking intercontinental 7,500 Hans Wijers 29 January 2013 travel to meetings per meeting The table below audited sets out the value of fees and benets received by the Non-Executive Directors in the form of cash and shares or ADS.
Further details of the Non-Executive Directors share allocation plan are set out on page 119.
For overseas-based Non-Executive Directors, this includes travel to meetings in the UK.
b Non-Executive Directors fees that are paid other than in GBP are converted using an exchange rate that is set annually based on the average rate for the last quarter of the year prior to payment.
The rate is reviewed if it moves signicantly during the year.
c Sir Philip Hampton and Urs Rohner joined the Board from 1 January 2015.
Vindi Banga joined the Board from 1 September 2015. d Sir Christopher Gent, Tom fide Swaan and Jing Ulrich all retired from the Board on 7 May 2015.
Sir Robert Wilson retired from the Board on 7 May 2014. e Sir Christopher Gents benets number includes 3,012 travel and hospitality costs incurred whilst attending GSK hosted events as previously agreed at the request of the company, after he retired on 7 May 2015.
